BlackBerry Ltd. (NASDAQ:BBRY): BMO Capital has lowered its BlackBerry estimates due largely to the lack of demand for the BB10 operating system; this is combined with the steady decline of BB7. The firm believes that BlackBerry should sell some or all of its assets, and the firm has lowered its price target to $7 from $8.
J.C. Penney Co. (NYSE:JCP): After conducting checks, Gilford Securities believes that J.C. Penney will achieve a 10-15 percent sales gain in the fourth quarter, which will act as a catalyst for J.C. Penney shares.
Dick’s Sporting Goods (NYSE:DKS): Cleveland Research said that it is incrementally more cautious on the fourth-quarter outlook for Dick’s Sporting Goods and believes that Dick’s is lowering its forward orders due to traffic issues and increased promotional activity.
Sarepta Therapeutics (NASDAQ:SRPT): RW Baird says that while Sarepta’s NDA application was denied by the Food and Drug Administration, the firm believes a compromise over a trial design will surface over the next few months. Although the timeframe for approval has been pushed out as long as two years, Baird thinks that a reasonable path forward could result in meaningful upside; the shares remain Outperform rated, but the price target is lowered to $22 from $63.